ArticleNeuro-oncology advances
Long-term outcome of nimustine-based chemotherapy for oligodendroglioma.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Combination chemotherapy of procarbazine, lomustine (CCNU), and vincristine (PCV), a standard treatment for oligodendroglioma, is associated with frequent adverse events. In Japan, only nimustine (ACNU), an analog of CCNU, is approved. This study aimed to evaluate the long-term outcomes of ACNU-based chemotherapy after maximal safe resection with deferred radiation therapy (RT) for oligodendrogliomas. Methods: This retrospective study included 50 patients diagnosed with IDH-mutant 1p/19q-codeleted oligodendroglioma of grades 2 (n = 27) or 3 (n = 23) between 2002 and 2022. Progression-free survival (PFS), overall survival (OS), and time to decline in performance status (deterioration-free survival [DFS]) were analyzed using the Kaplan-Meier method. Results: Postoperative chemotherapy was administered to 94% of patients (procarbazine, ACNU, and vincristine [PAV], n = 24; ACNU, n = 22; temozolomide [TMZ], n = 1; excluded). Median follow-ups were 142.9 and 50.6 months for PAV and ACNU groups, respectively. Ten-year PFS rates were 54.2% and 30.0% for grades 2 and 3 tumors, respectively ( Conclusions: ACNU monotherapy has a similar efficacy to PAV and tolerability to TMZ, suggesting that it is the most favorable chemotherapeutic option currently available in Japan, considering its risk-benefit profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.